2019-2026年代謝領域的合作與授權協議

Metabolic Collaboration and Licensing Deals 2019-2026

出版日期: 2026年10月01日 | 出版商:

Current Partnering | 英文 300+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

讓我們利用 649 個真實世界的合作與許可協議案例的信息，來了解代謝領域合作的趨勢。

《2019-2026 年代謝領域的合作與許可協議》提供了有關 649 項與代謝相關資產、技術和開發計劃的合作交易的全面資訊。

代謝性疾病是製藥和生物技術領域創新的關鍵領域，涵蓋了大規模的慢性疾病患者群體、不斷發展的治療方法以及在多種適應症和技術方面的重要商業性機會。

本報告將這些合作活動匯總到一個資源中，使用戶能夠了解哪些公司正在合作，哪些與代謝疾病相關的機會正在吸引關注，交易結構是什麼，披露了哪些財務條款，以及交易如何根據治療適應症、技術和開發階段而有所不同。

這份報告不只是簡單地列出了交易清單；它結合了全面的市場交易分析和財務基準、主要交易商的信息、詳細的交易記錄以及公開的合約文件。

本報告為代謝領域的業務發展、許可、研究和評估、公司策略、研發策略、競爭情報分析以及參與合作的法律團隊提供了實用的資訊來源和基準資源。

了解代謝疾病領域的合作趨勢。

本報告分析了2019年至2026年代謝領域的交易情況，內容包括：

代謝相關夥伴關係的年度趨勢
按交易類型分類的交易趨勢
按行業
合作關係發展階段
技術類型
治療指徵
代謝領域最活躍的交易商
根據已披露的交易金額，主要交易
代謝領域合作活動的趨勢
這使用戶能夠確定他們的活動集中在哪些方面，並了解哪些公司、技術、開發階段和治療領域正在吸引合作興趣。
代謝相關交易的財務狀況基準
財務條款可能因所涉資產、開發階段、技術、授予的權利以及交易的整體結構而有很大差異。

本報告對已揭露的財務狀況進行了詳細分析，包括以下內容：

交易總額
預付款
里程碑付款
版稅率
透過分析這些基準背後的具體交易，用戶可以更全面地了解所揭露的經濟數據背後的經濟狀況。
這為內部基準測試、機會評估、交易準備和談判提供了現實的參考點。
財務基準只有在結合類似交易的結構和情況進行解讀時才最有用，而不僅僅是作為平均值。本報告提供了建立這種背景所需的基礎交易資訊。
確定代謝領域的關鍵交易商和有潛力的合作夥伴。
本報告列出了代謝領域合作活動最活躍的公司，並提供交易歷史記錄，以便用戶可以調查其過去的活動。

這有助於用戶識別以下內容：

積極尋求代謝領域機會的公司
有潛力的許可和合作研究夥伴
我們曾多次與相關組織合作，共同研究相關代謝疾病的適應症。
積極參與開發過程的公司
對特定技術、標靶或治療方法感興趣的交易商。
競爭對手正在推廣相關的外部創新策略
對於尋求代謝相關資產和技術合作夥伴的公司而言，過去的交易歷史可以提供寶貴的見解，了解哪些組織對類似的機會表現出了興趣。
本研究比較了代謝疾病不同適應症和標靶的合作趨勢。
代謝性疾病涵蓋多種適應症和治療標靶，其科學、臨床和商業性趨勢各不相同。
本報告按治療適應症和治療標靶分析合作關係，使用戶能夠專注於與特定項目和策略關注事項最相關的交易，而不是僅依賴代謝疾病的廣泛基準。
透過結合技術和發展階段的分析，用戶可以找到更有意義的可比較交易和潛在的未來合作夥伴。
了解代謝疾病領域合作協議的結構
本報告涵蓋合作研究、授權、開發、調查和其他合作交易。

根據交易詳情和資訊披露，用戶可以調查以下方面：

授予和保留的權利
研發職責
授權權
獨家版權
區域權利
智慧財產
發展和監管義務
負責生產和供應
商業化權利
金錢補償
里程碑和版稅
管治
合約期限和終止條款
這些現實世界的例子為考慮與代謝相關的合作的適當框架提供了寶貴的見解。
從實際合約文件中學習
本報告在有資料的情況下，提供了對選定的代謝相關交易的基礎合約文件的存取。

這些合約提供的資訊遠比簡單的標題公告所能展現的要詳細得多，使用戶能夠檢驗公司如何記錄諸如以下事項：

權利範圍
發展義務
智慧財產
獨家版權
財務狀況
里程碑觸發條件
特許權使用費規定
商業化權利
合約終止及其他談判事項
對於準備和談判與代謝相關的合作研究或許可協議的團隊來說，獲取實際的合約措辭可以提供關於類似交易實際結構方式的寶貴見解。
綜合代謝相關交易目錄
本報告包含一個綜合目錄，涵蓋 649 項與代謝相關的合作研究和許可協議，為識別相關的領先交易提供了詳細的資訊來源。

在以下條件下可以查看交易記錄：

公司
技術類型
治療適應症或標靶
合約揭露狀態
每筆交易都與其底層交易記錄相關聯，從而可以存取詳細的交易資訊和相關的合約文件（如有）。
誰該使用這份報告？
業務拓展與授權團隊
尋找與代謝相關的類似交易、有前景的合作夥伴以及相關的交易結構。
探勘與評估團隊
我們將確定哪些公司正在積極探索與代謝相關的商業機會，涵蓋相關適應症、技術、標靶和開發階段。
尋求合作夥伴的生技公司
找出對類似代謝相關資產或技術表現出明顯興趣的組織。
企業策略與研發策略團隊
我們將了解我們的競爭對手和潛在的未來合作夥伴如何透過外部創新來建立其與新陳代謝相關的產品組合。
競爭情報與市場情報團隊
按公司、適應症、目標、開發階段和技術追蹤合作趨勢，以了解不斷變化的策略重點。
法律及交易團隊
我們將仔細審查公開的合約和以往的合約結構，以幫助您準備和談判交易。
我們將市場範圍內的代謝相關資訊轉化為公司特定的洞察。
對於符合資格的客戶，Current Partnering 不僅會提供報告，還會為高階主管提供客製化的合作關係簡報。
本簡報將把與新陳代謝相關的基礎交易資訊應用於您自己的資產、技術、指標、目標或合作目標。
如有需要，我們可以提供相關的類似交易、有前景的合作夥伴、競爭對手的活動、發展階段分析、交易結構、財務基準、忠誠度分析、合約見解以及其他專門為您選擇的資訊。
請索取樣本或聯絡 Current Partnering 討論本報告的內容以及我們是否可以為貴公司提供客製化分析。

The report brings this partnering activity together in one resource, enabling users to understand who is partnering, which metabolic opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in metabolic partnering.

Understand the metabolic partnering landscape

The report analyzes metabolic dealmaking from 2019 to 2026, including:

Trends in metabolic partnering by year
Deal activity by deal type
Industry sector
Stage of development at the time of partnering
Technology type
Therapeutic indication
Most active metabolic dealmakers
Leading deals by disclosed value
How metabolic partnering activity is evolving
This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
Benchmark metabolic deal financials
Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

Headline deal values
Upfront payments
Milestone payments
Royalty rates
Users can investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading metabolic dealmakers and prospective partners
The report identifies the most active companies in metabolic partnering and provides transaction histories that enable users to investigate their previous activity.

This can help users identify:

Companies actively seeking metabolic opportunities
Prospective licensing and collaboration partners
Organizations repeatedly partnering in relevant metabolic indications
Companies active at relevant stages of development
Dealmakers demonstrating interest in particular technologies, targets or therapeutic approaches
Competitors pursuing related external innovation strategies
For companies seeking to partner a metabolic asset or technology, previous transaction activity can provide useful evidence of which organizations have demonstrated an appetite for comparable opportunities.
Compare partnering activity across metabolic indications and targets
Metabolic disease encompasses multiple indications and therapeutic targets with differing scientific, clinical and commercial dynamics.
The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad metabolic benchmarks and focus on transactions most relevant to a particular program or strategic interest.
Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
Understand how metabolic agreements are structured
The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

Rights granted and retained
Research and development responsibilities
Licensing rights
Exclusivity
Geographic rights
Intellectual property
Development and regulatory obligations
Manufacturing and supply responsibilities
Commercialization rights
Financial consideration
Milestones and royalties
Governance
Term and termination provisions
These real-world examples provide useful reference points when considering the appropriate structure for a metabolic partnership.
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected metabolic transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

Scope of rights
Development obligations
Intellectual property
Exclusivity
Financial terms
Milestone triggers
Royalty provisions
Commercialization rights
Termination and other negotiated provisions
For teams preparing or negotiating a metabolic collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
Comprehensive metabolic deal directory
The report includes a comprehensive directory of 649 metabolic collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.

Deals can be reviewed by:

Company
Technology type
Therapeutic indication or target
Contract availability
Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
Who should use this report?
Business Development and Licensing teams
Identify comparable metabolic transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking metabolic opportunities across relevant indications, technologies, targets and development stages.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable metabolic assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and prospective partners are building metabolic portfolios through external innovation.
Competitive and Market Intelligence teams
Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide metabolic intelligence into company-specific insight
For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
The briefing applies the underlying metabolic deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.